clinical trial · NCT06697197
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb·phase2·recruiting·n = 413
Advanced Solid TumorsBMS-986482Nivolumab and rHuPH20Nivolumab/relatlimab/rHuPH20Bevacizumab
brief summary
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
started
Feb 17, 2025
primary completion
Jan 4, 2029
completion
Jan 5, 2029
last updated
Feb 3, 2026
official title
A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol